Bristol-Myers Squibb Co. (NYSE:BMY)

CAPS Rating: 4 out of 5

Bristol-Myers Squibb discovers, develops, licenses, makes, and sells pharmaceuticals, with particular success in cardiovascular treatments.

Results 1 - 20 of 227 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar foolmelgoner (< 20) Submitted: 12/15/2014 8:49:32 PM : Outperform Start Price: $58.30 BMY Score: +1.15

Solid pipeline, good management

Recs

0
Member Avatar AnsgarJohn (98.14) Submitted: 11/16/2014 8:54:06 AM : Underperform Start Price: $57.73 BMY Score: -4.87

Bristol-Myers a favorite of Jima Cramer and Fools, but seems to be getting ahead of itself. PE almost 40, not much growth. End ASAP http://www.gurufocus.com/stock/BMY&summary

Recs

0
Member Avatar mrgekko (42.99) Submitted: 11/7/2014 4:56:31 AM : Outperform Start Price: $58.26 BMY Score: +3.57

some great phase 3 drugs and in the right areas

Recs

0
Member Avatar MightyMinnow (35.80) Submitted: 11/3/2014 9:06:30 AM : Underperform Start Price: $58.31 BMY Score: -2.85

unhealthy peg

Recs

0
Member Avatar JeffRossMD (< 20) Submitted: 10/30/2014 12:44:24 PM : Outperform Start Price: $58.26 BMY Score: +1.39

The biotech space is just heating up as new technologies are revolutionizing cancer and chronic disease processes.

Recs

0
Member Avatar mikeayu (< 20) Submitted: 10/14/2014 7:06:01 PM : Outperform Start Price: $48.36 BMY Score: +15.22

Huge upside from cancel drugs.

Recs

0
Member Avatar afewgoodstocks14 (< 20) Submitted: 10/1/2014 2:23:35 PM : Outperform Start Price: $50.52 BMY Score: +11.68

Div. (Yield) $1.44 (2.8%)

Recs

0
Member Avatar Herbstmd (51.13) Submitted: 8/22/2014 11:55:42 AM : Outperform Start Price: $49.68 BMY Score: +19.76

Developing great new cancer drugs called PD1, which may revolutionize cancer therapy.

Recs

0
Member Avatar Kenji94 (47.61) Submitted: 8/19/2014 1:29:19 AM : Underperform Start Price: $49.81 BMY Score: -18.68

There is a disconnection between price and fundamentals. I would like to own the company, but not at this price.

Recs

0
Member Avatar hydn (< 20) Submitted: 5/16/2014 10:28:57 AM : Outperform Start Price: $48.08 BMY Score: +17.06

Solid demand for ever improving products.

Recs

0
Member Avatar Johnybe (67.47) Submitted: 5/14/2014 9:46:28 PM : Outperform Start Price: $48.80 BMY Score: +16.15

strong player in this sector

Recs

0
Member Avatar DRGRNR (< 20) Submitted: 4/15/2014 7:52:17 PM : Outperform Start Price: $47.73 BMY Score: +17.09

I've owned BMY for 30 years, always a strong performer.

Recs

0
Member Avatar bassnman45 (36.77) Submitted: 1/2/2014 9:30:25 PM : Outperform Start Price: $20.86 BMY Score: +124.32

buy, hold long term and monitor

Recs

1
Member Avatar johnclanaro (< 20) Submitted: 10/28/2013 3:54:27 PM : Outperform Start Price: $50.68 BMY Score: +3.76

recent upgrade. good pipeline.

Recs

1
Member Avatar gilmomp1 (55.81) Submitted: 10/16/2013 9:38:21 PM : Outperform Start Price: $47.23 BMY Score: +9.27

I bought 100 shares of this company pre 1995 and now own 188 shares by reinvesting my dividends. Now that I'm nearing retirement that dividend looks pretty good!

Recs

1
Member Avatar nancytroi (< 20) Submitted: 10/2/2013 11:43:34 AM : Outperform Start Price: $45.37 BMY Score: +12.63

Continues finding new drugs to fight cancers

Recs

0
Member Avatar lg7691 (30.63) Submitted: 7/21/2013 1:34:10 PM : Outperform Start Price: $42.71 BMY Score: +21.61

7/21/13 44.19 drug stock

Recs

2
Member Avatar usubanas (99.70) Submitted: 5/15/2013 2:35:44 AM : Outperform Start Price: $40.43 BMY Score: +26.44

I'm buying this tomorrow because of PD-1

Recs

0
Member Avatar DonkeyJunk (24.69) Submitted: 5/5/2013 10:39:09 PM : Underperform Start Price: $38.41 BMY Score: -31.69

Stock with a PE of almost 50 in an on-average overvalued market due for a significant pullback. With a company this size, the increase in revenue would have to be astronomical to justify the price.

Recs

0
Member Avatar mfwatcher (< 20) Submitted: 2/9/2013 10:45:25 AM : Outperform Start Price: $34.99 BMY Score: +39.11

Product pipeline has it positioned to outperform its peers during the recovery period.

Featured Broker Partners


Advertisement